In addition, non-muscle-invasive BC related genes FGFR3 mutated in both primary tumors (2/20, 10.0%) and relapsed tumors (3/17, 17.6%) and HRAS altered in both primary tumors (6/20, 30.0%) and recurring tumors (1/17, 5.9%). This evidence concerns the gene FGFR3 and breast cancer.